June 1, 2023 07:28 AM EDT
Bioregnum

Who's con­fi­dent­ly in­vest­ing in biotech star­tups dur­ing these tense days? We've got some an­swers

John Carroll

Editor & Founder

We’ve got a change­up to our event sched­ule in Boston next week, where we’ll be do­ing a mix of live/stream­ing events at our base …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

No­vavax re­sponds to FDA’s tri­al ask, with Covid vac­cine strain up­dates un­der scruti­ny

GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer

Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B

Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz 

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times